Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Oligoastrocytic tumor

MedGen UID:: 79185
•Concept ID:: C0280793
•: Neoplastic Process

Synonyms:	Mixed Oligodendroglioma Astrocytoma; Mixed Oligodendroglioma-Astrocytoma; Mixed Oligodendroglioma-Astrocytomas; Oligodendroglioma-Astrocytoma, Mixed; Oligodendroglioma-Astrocytomas, Mixed
SNOMED CT:	Oligoastrocytoma (22217002)

Orphanet:	ORPHA251651

Definition

A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO) [from NCI]

Term Hierarchy

GTR
MeSH
Orphanet

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVOligoastrocytic tumor

Malignant neoplastic disease
- Malignant neoplasm of nervous system
  - Malignant neoplasm of the central nervous system
    - Glioma
      - Low grade glioma
        Grade II glioma
        Oligoastrocytic tumor
        Anaplastic oligoastrocytoma
        Childhood Anaplastic Oligoastrocytoma
        Recurrent Childhood Anaplastic Oligoastrocytoma
        Recurrent Anaplastic Oligoastrocytoma
        Childhood Oligoastrocytoma
        Recurrent Childhood Oligoastrocytoma
        Oligoastrocytoma
        Recurrent Oligoastrocytoma

Follow this link to review classifications for Oligoastrocytic tumor in Orphanet.

Professional guidelines

PubMed

Molecular diagnostics as a tool to personalize treatment in adult glioma patients.

Jeuken JW, van der Maazen RW, Wesseling P
Technol Cancer Res Treat 2006 Jun;5(3):215-29. doi: 10.1177/153303460600500305. PMID: 16700618

Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity.

Walker C, du Plessis DG, Joyce KA, Machell Y, Thomson-Hehir J, Al Haddad SA, Broome JC, Warnke PC
Clin Cancer Res 2003 Oct 15;9(13):4841-51. PMID: 14581356

See all (2)

Recent clinical studies

Etiology

The Recurrent-Specific Regulation Network of Prognostic Stemness-Related Signatures in Low-Grade Glioma.

Li J, Zhou M, Huang D, Lin R, Cui X, Chen S, Yao Y, Xian S, Wang S, Fu Q, Zhu J, Yue X, Huang R, Qi E, Huang Z
Dis Markers 2023;2023:2243928. Epub 2023 Jan 17 doi: 10.1155/2023/2243928. PMID: 36703644 Free PMC Article

Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005.

Fuentes-Raspall R, Vilardell L, Perez-Bueno F, Joly C, Garcia-Gil M, Garcia-Velasco A, Marcos-Gragera R
J Neurooncol 2011 Jan;101(1):117-23. Epub 2010 Jun 11 doi: 10.1007/s11060-010-0240-7. PMID: 20544374

Molecular neuropathology of low-grade gliomas and its clinical impact.

Riemenschneider MJ, Reifenberger G
Adv Tech Stand Neurosurg 2010;35:35-64. doi: 10.1007/978-3-211-99481-8_2. PMID: 20102110

Oligodendroglial tumors.

Chowdhary S, Chamberlain MC
Expert Rev Neurother 2006 Apr;6(4):519-32. doi: 10.1586/14737175.6.4.519. PMID: 16623651

Prognostic factors for low-grade gliomas.

Stupp R, Janzer RC, Hegi ME, Villemure JG, Mirimanoff RO
Semin Oncol 2003 Dec;30(6 Suppl 19):23-8. doi: 10.1053/j.seminoncol.2003.11.029. PMID: 14765381

See all (20)

Diagnosis

H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.

Ammendola S, Caldonazzi N, Simbolo M, Piredda ML, Brunelli M, Poliani PL, Pinna G, Sala F, Ghimenton C, Scarpa A, Barresi V
Virchows Arch 2021 Nov;479(5):987-996. Epub 2021 Jun 24 doi: 10.1007/s00428-021-03134-1. PMID: 34165590 Free PMC Article

Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005.

Molecular neuropathology of low-grade gliomas and its clinical impact.

Riemenschneider MJ, Reifenberger G
Adv Tech Stand Neurosurg 2010;35:35-64. doi: 10.1007/978-3-211-99481-8_2. PMID: 20102110

Oligodendroglial tumors.

Chowdhary S, Chamberlain MC
Expert Rev Neurother 2006 Apr;6(4):519-32. doi: 10.1586/14737175.6.4.519. PMID: 16623651

Prognostic factors for low-grade gliomas.

Stupp R, Janzer RC, Hegi ME, Villemure JG, Mirimanoff RO
Semin Oncol 2003 Dec;30(6 Suppl 19):23-8. doi: 10.1053/j.seminoncol.2003.11.029. PMID: 14765381

See all (21)

Therapy

Cyclin D1 gene G870A variants and primary brain tumors.

Zeybek U, Yaylim I, Ozkan NE, Korkmaz G, Turan S, Kafadar D, Cacina C, Kafadar AM
Asian Pac J Cancer Prev 2013;14(7):4101-6. doi: 10.7314/apjcp.2013.14.7.4101. PMID: 23991960

Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).

Vordermark D, Ruprecht K, Rieckmann P, Roggendorf W, Vince GH, Warmuth-Metz M, Kölbl O, Flentje M
BMC Cancer 2006 Oct 18;6:247. doi: 10.1186/1471-2407-6-247. PMID: 17049083 Free PMC Article

Oligodendroglial tumors.

Chowdhary S, Chamberlain MC
Expert Rev Neurother 2006 Apr;6(4):519-32. doi: 10.1586/14737175.6.4.519. PMID: 16623651

Initial chemotherapy in gliomatosis cerebri.

Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY; ANOCEF group
Neurology 2004 Jul 27;63(2):270-5. doi: 10.1212/01.wnl.0000129985.39973.e4. PMID: 15277619

See all (4)

Prognosis

The Recurrent-Specific Regulation Network of Prognostic Stemness-Related Signatures in Low-Grade Glioma.

Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005.

Molecular neuropathology of low-grade gliomas and its clinical impact.

Riemenschneider MJ, Reifenberger G
Adv Tech Stand Neurosurg 2010;35:35-64. doi: 10.1007/978-3-211-99481-8_2. PMID: 20102110

Molecular pathogenesis of oligodendroglial tumors.

Jeuken JW, von Deimling A, Wesseling P
J Neurooncol 2004 Nov;70(2):161-81. doi: 10.1007/s11060-004-2748-1. PMID: 15674476

Prognostic factors for low-grade gliomas.

Stupp R, Janzer RC, Hegi ME, Villemure JG, Mirimanoff RO
Semin Oncol 2003 Dec;30(6 Suppl 19):23-8. doi: 10.1053/j.seminoncol.2003.11.029. PMID: 14765381

See all (21)

Clinical prediction guides

H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.

Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event.

Lass U, Nümann A, von Eckardstein K, Kiwit J, Stockhammer F, Horaczek JA, Veelken J, Herold-Mende C, Jeuken J, von Deimling A, Mueller W
PLoS One 2012;7(7):e41298. Epub 2012 Jul 23 doi: 10.1371/journal.pone.0041298. PMID: 22844452 Free PMC Article

Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005.

Initial chemotherapy in gliomatosis cerebri.

Prognostic factors for low-grade gliomas.

Stupp R, Janzer RC, Hegi ME, Villemure JG, Mirimanoff RO
Semin Oncol 2003 Dec;30(6 Suppl 19):23-8. doi: 10.1053/j.seminoncol.2003.11.029. PMID: 14765381

See all (12)

Recent systematic reviews

Clinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data.

Georgakis MK, Tsivgoulis G, Spinos D, Dimitriou NG, Kyritsis AP, Herrlinger U, Petridou ET
J Neurooncol 2018 Nov;140(2):467-475. Epub 2018 Aug 16 doi: 10.1007/s11060-018-2976-4. PMID: 30117023

See all (1)

MedGen

National Center for Biotechnology Information

Send to:

Oligoastrocytic tumor

Definition

Term Hierarchy

Professional guidelines

PubMed

Recent clinical studies

Etiology

Diagnosis

Therapy

Prognosis

Clinical prediction guides

Recent systematic reviews

Supplemental Content

Table of contents

Clinical resources

Practice guidelines

Consumer resources

Reviews

Related information

Recent activity